Chimeric Hands Back CHM CLTX to City of Hope to Sharpen Focus on Core Cell Therapy Programs

Chimeric Therapeutics Ltd. ( (AU:CHM) ) has provided an update.

Chimeric Therapeutics has returned the Chlorotoxin (CHM CLTX) CAR T-cell therapy asset to City of Hope, which will regain full ownership and control of the intellectual property and associated program. The move follows a strategic portfolio review in which CHM CLTX was overtaken by other clinical-stage assets in development priority and is positioned as a disciplined capital management decision.

The company will now concentrate resources on advancing its core programs, particularly the first-in-class CHM CDH17 CAR T therapy and its CORE-NK platform, which are seen as having stronger potential for clinical impact and commercial scalability. Management emphasised that streamlining the portfolio should enable more efficient capital deployment and support progress through key development milestones, with the aim of enhancing long-term shareholder value and strengthening Chimeric’s position in cell therapy oncology.

The most recent analyst rating on (AU:CHM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Chimeric Therapeutics Ltd. stock, see the AU:CHM Stock Forecast page.

More about Chimeric Therapeutics Ltd.

Chimeric Therapeutics Limited is an Australian clinical-stage cell therapy company focused on developing innovative treatments for cancer. Its diversified portfolio includes first-in-class autologous CAR T-cell therapies and best-in-class allogeneic NK cell therapies, with three clinical-stage programs targeting multiple oncology indications, including the lead CHM CDH17 CAR T and the CORE-NK platform.

Technical Sentiment Signal: Sell

Current Market Cap: A$8.84M

Find detailed analytics on CHM stock on TipRanks’ Stock Analysis page.